Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS, Kochi, India.
J Liposome Res. 2023 Dec;33(4):410-424. doi: 10.1080/08982104.2023.2199068. Epub 2023 Apr 19.
High local delivery of anti-infectives to the lungs is required for activity against infections of the lungs. The present pandemic has highlighted the potential of pulmonary delivery of anti-infective agents as a viable option for infections like Covid-19, which specifically causes lung infections and mortality. To prevent infections of such type and scale in the future, target-specific delivery of drugs to the pulmonary region is a high-priority area in the field of drug delivery. The suboptimal effect of oral delivery of anti-infective drugs to the lungs due to the poor biopharmaceutical property of the drugs makes this delivery route very promising for respiratory infections. Liposomes have been used as an effective delivery system for drugs due to their biocompatible and biodegradable nature, which can be used effectively for target-specific drug delivery to the lungs. In the present review, we focus on the use of liposomal drug delivery of anti-infectives for the acute management of respiratory infections in the wake of Covid-19 infection.
需要将抗感染药物高浓度递送至肺部，以有效对抗肺部感染。本次大流行凸显了肺部递呈抗感染药物的潜力，这是治疗 COVID-19 等肺部感染和死亡的可行选择。为防止将来发生此类规模的感染，将药物靶向递送至肺部区域是药物递呈领域的重中之重。由于抗感染药物的生物药剂学性质较差，口服递送至肺部的效果不佳，因此对于呼吸道感染，这种递药途径很有前景。由于具有生物相容性和可生物降解性，脂质体可用作药物的有效递呈系统，可有效将药物靶向递送至肺部。在本综述中，我们重点关注脂质体药物递呈系统在 COVID-19 感染后急性管理呼吸道感染中的应用。
